vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Skyworks Solutions (SWKS). Click either name above to swap in a different company.

Skyworks Solutions is the larger business by last-quarter revenue ($1.0B vs $749.2M, roughly 1.4× CLOVER HEALTH INVESTMENTS, CORP.). Skyworks Solutions runs the higher net margin — 7.6% vs 3.6%, a 4.0% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (62.0% vs 8.6%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (45.0% CAGR vs -0.5%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Skyworks Solutions, Inc. is an American semiconductor company headquartered in Irvine, California, United States. The company's shares are listed on the Nasdaq Global Select Market under the ticker symbol SWKS and is a constituent of the S&P 500.

CLOV vs SWKS — Head-to-Head

Bigger by revenue
SWKS
SWKS
1.4× larger
SWKS
$1.0B
$749.2M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+53.4% gap
CLOV
62.0%
8.6%
SWKS
Higher net margin
SWKS
SWKS
4.0% more per $
SWKS
7.6%
3.6%
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
45.0%
-0.5%
SWKS

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CLOV
CLOV
SWKS
SWKS
Revenue
$749.2M
$1.0B
Net Profit
$27.3M
$79.2M
Gross Margin
41.3%
Operating Margin
3.6%
10.0%
Net Margin
3.6%
7.6%
Revenue YoY
62.0%
8.6%
Net Profit YoY
15.3%
EPS (diluted)
$0.05
$0.53

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
SWKS
SWKS
Q1 26
$749.2M
$1.0B
Q4 25
$487.7M
$1.1B
Q3 25
$496.6M
Q2 25
$477.6M
$965.0M
Q1 25
$462.3M
$953.2M
Q4 24
$337.0M
$1.1B
Q3 24
$331.0M
$1.0B
Q2 24
$356.3M
$905.5M
Net Profit
CLOV
CLOV
SWKS
SWKS
Q1 26
$27.3M
$79.2M
Q4 25
$-49.3M
$141.4M
Q3 25
$-24.4M
Q2 25
$-10.6M
$105.0M
Q1 25
$-1.3M
$68.7M
Q4 24
$-22.1M
$162.0M
Q3 24
$-9.2M
$60.5M
Q2 24
$7.4M
$120.9M
Gross Margin
CLOV
CLOV
SWKS
SWKS
Q1 26
41.3%
Q4 25
40.7%
Q3 25
Q2 25
41.6%
Q1 25
41.1%
Q4 24
41.4%
Q3 24
24.5%
41.9%
Q2 24
30.3%
40.2%
Operating Margin
CLOV
CLOV
SWKS
SWKS
Q1 26
3.6%
10.0%
Q4 25
-10.1%
10.1%
Q3 25
-4.9%
Q2 25
-2.2%
11.5%
Q1 25
-0.3%
10.2%
Q4 24
-6.4%
16.9%
Q3 24
-2.7%
5.8%
Q2 24
2.0%
14.4%
Net Margin
CLOV
CLOV
SWKS
SWKS
Q1 26
3.6%
7.6%
Q4 25
-10.1%
12.9%
Q3 25
-4.9%
Q2 25
-2.2%
10.9%
Q1 25
-0.3%
7.2%
Q4 24
-6.6%
15.2%
Q3 24
-2.8%
5.9%
Q2 24
2.1%
13.4%
EPS (diluted)
CLOV
CLOV
SWKS
SWKS
Q1 26
$0.05
$0.53
Q4 25
$0.95
Q3 25
Q2 25
$0.70
Q1 25
$0.43
Q4 24
$1.00
Q3 24
$0.36
Q2 24
$0.75

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
SWKS
SWKS
Cash + ST InvestmentsLiquidity on hand
$177.6M
$1.6B
Total DebtLower is stronger
$496.6M
Stockholders' EquityBook value
$339.4M
$5.8B
Total Assets
$697.7M
$7.9B
Debt / EquityLower = less leverage
0.09×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
SWKS
SWKS
Q1 26
$177.6M
$1.6B
Q4 25
$78.3M
$1.4B
Q3 25
Q2 25
$1.3B
Q1 25
$1.5B
Q4 24
$194.5M
$1.7B
Q3 24
$288.0M
$1.6B
Q2 24
$254.8M
$1.3B
Total Debt
CLOV
CLOV
SWKS
SWKS
Q1 26
$496.6M
Q4 25
$496.4M
Q3 25
Q2 25
$496.2M
Q1 25
$995.1M
Q4 24
$994.7M
Q3 24
$994.3M
Q2 24
$994.0M
Stockholders' Equity
CLOV
CLOV
SWKS
SWKS
Q1 26
$339.4M
$5.8B
Q4 25
$308.7M
$5.8B
Q3 25
$340.9M
Q2 25
$344.2M
$5.7B
Q1 25
$336.1M
$5.9B
Q4 24
$341.1M
$6.4B
Q3 24
$342.2M
$6.3B
Q2 24
$324.9M
$6.3B
Total Assets
CLOV
CLOV
SWKS
SWKS
Q1 26
$697.7M
$7.9B
Q4 25
$541.0M
$7.9B
Q3 25
$559.7M
Q2 25
$575.0M
$7.7B
Q1 25
$583.7M
$7.9B
Q4 24
$580.7M
$8.3B
Q3 24
$653.0M
$8.3B
Q2 24
$674.2M
$8.2B
Debt / Equity
CLOV
CLOV
SWKS
SWKS
Q1 26
0.09×
Q4 25
0.09×
Q3 25
Q2 25
0.09×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.16×
Q2 24
0.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
SWKS
SWKS
Operating Cash FlowLast quarter
$395.5M
Free Cash FlowOCF − Capex
$339.0M
FCF MarginFCF / Revenue
32.7%
Capex IntensityCapex / Revenue
5.5%
Cash ConversionOCF / Net Profit
4.99×
TTM Free Cash FlowTrailing 4 quarters
$1.1B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
SWKS
SWKS
Q1 26
$395.5M
Q4 25
$-66.9M
$200.0M
Q3 25
$12.1M
Q2 25
$5.4M
$314.2M
Q1 25
$-16.3M
$409.4M
Q4 24
$34.8M
$377.2M
Q3 24
$50.0M
$476.1M
Q2 24
$44.8M
$273.4M
Free Cash Flow
CLOV
CLOV
SWKS
SWKS
Q1 26
$339.0M
Q4 25
$-69.0M
$144.0M
Q3 25
$11.4M
Q2 25
$4.8M
$252.7M
Q1 25
$-16.5M
$370.9M
Q4 24
$33.3M
$338.2M
Q3 24
$49.6M
$393.3M
Q2 24
$44.4M
$249.0M
FCF Margin
CLOV
CLOV
SWKS
SWKS
Q1 26
32.7%
Q4 25
-14.1%
13.1%
Q3 25
2.3%
Q2 25
1.0%
26.2%
Q1 25
-3.6%
38.9%
Q4 24
9.9%
31.7%
Q3 24
15.0%
38.4%
Q2 24
12.5%
27.5%
Capex Intensity
CLOV
CLOV
SWKS
SWKS
Q1 26
5.5%
Q4 25
0.4%
5.1%
Q3 25
0.1%
Q2 25
0.1%
6.4%
Q1 25
0.0%
4.0%
Q4 24
0.5%
3.6%
Q3 24
0.1%
8.1%
Q2 24
0.1%
2.7%
Cash Conversion
CLOV
CLOV
SWKS
SWKS
Q1 26
4.99×
Q4 25
1.41×
Q3 25
Q2 25
2.99×
Q1 25
5.96×
Q4 24
2.33×
Q3 24
7.87×
Q2 24
6.04×
2.26×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

SWKS
SWKS

Sales Channel Through Intermediary$915.6M88%
Sales Channel Directly To Consumer$119.8M12%

Related Comparisons